C13H19N3O7
M.W.: 329.31

    EIDD-2801 is an orally bioavailable NHC-prodrug. NHC is potently antiviral against SARS-CoV-2, MERS-CoV and SARS-CoV in primary human epithelial cell cultures without cytotoxicity. NHC is effective against remdesivir (RDV)-resistant vi-rus and multiple distinct zoonotic CoV. NHC antiviral activity is associated with increased viral mutation rates.

 

    EIDD-2801 is efficiently hydrolyzed in vivo after absorption, resulting in detection of only free NHC in plasma. Therapeutic EIDD-2801 is potently antiviral against SARS-CoV in vivo but the degree of clinical benefit is dependent on the time of initiation post-infection. EIDD-2801 robustly reduces MERS-CoV infectious titers, viral RNA, and pathogenesis under both prophylactic and early therapeutic conditions

Sheahan TP, et al. Sci Transl Med. 2020 Apr 29;12(541).
Toots M, et al. Sci Transl Med. 2019 Oct 23;11(515).